Compounds > deferasirox
Page last updated: 2024-09-05

deferasirox and 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone

deferasirox has been researched along with 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone in 1 studies

Compound Research Comparison

Studies
(deferasirox)		Trials
(deferasirox)		Recent Studies (post-2010)
(deferasirox)		Studies
(2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone)		Trials
(2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone)		Recent Studies (post-2010) (2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone)
83213657223010

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ammosova, T; Charles, S; Debebe, Z; Gordeuk, VR; Jerebtsova, M; Kurantsin-Mills, J; Nekhai, S; Niu, X; Ray, PE; Richardson, DR1

Other Studies

1 other study(ies) available for deferasirox and 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone

ArticleYear
Iron chelators ICL670 and 311 inhibit HIV-1 transcription.
    Virology, 2007, Oct-25, Volume: 367, Issue:2

    Topics: Benzoates; Cells, Cultured; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Deferasirox; Gene Expression Regulation, Viral; HIV-1; Humans; Iron; Iron Chelating Agents; Isoniazid; Transcription, Genetic; Triazoles; Virus Replication

2007